AU2017277897B2 - Microparticles comprising a sulphur-containing compound - Google Patents

Microparticles comprising a sulphur-containing compound Download PDF

Info

Publication number
AU2017277897B2
AU2017277897B2 AU2017277897A AU2017277897A AU2017277897B2 AU 2017277897 B2 AU2017277897 B2 AU 2017277897B2 AU 2017277897 A AU2017277897 A AU 2017277897A AU 2017277897 A AU2017277897 A AU 2017277897A AU 2017277897 B2 AU2017277897 B2 AU 2017277897B2
Authority
AU
Australia
Prior art keywords
microparticles
cysteamine
composition
stabilizing agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017277897A
Other languages
English (en)
Other versions
AU2017277897A1 (en
Inventor
Deborah O'neil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Publication of AU2017277897A1 publication Critical patent/AU2017277897A1/en
Application granted granted Critical
Publication of AU2017277897B2 publication Critical patent/AU2017277897B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Accessories For Mixers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2017277897A 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound Active AU2017277897B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
GB1609940.0 2016-06-07
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (2)

Publication Number Publication Date
AU2017277897A1 AU2017277897A1 (en) 2018-12-20
AU2017277897B2 true AU2017277897B2 (en) 2022-09-08

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277897A Active AU2017277897B2 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Country Status (16)

Country Link
US (1) US11369568B2 (enExample)
EP (1) EP3463325B1 (enExample)
JP (1) JP7195934B2 (enExample)
KR (1) KR102412212B1 (enExample)
CN (2) CN122297397A (enExample)
AU (1) AU2017277897B2 (enExample)
BR (1) BR112018075221B1 (enExample)
CA (2) CA3026743C (enExample)
DK (1) DK3463325T3 (enExample)
ES (1) ES2965017T3 (enExample)
FI (1) FI3463325T3 (enExample)
GB (1) GB201609940D0 (enExample)
MX (1) MX2018014278A (enExample)
SG (1) SG11201810934TA (enExample)
WO (1) WO2017212249A1 (enExample)
ZA (1) ZA201807852B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
EP3866775B1 (en) * 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
JP2023540190A (ja) 2020-09-03 2023-09-22 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 低吸湿性活性粉末組成物
US20230346696A1 (en) * 2020-09-03 2023-11-02 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
AU2022405530A1 (en) * 2021-12-07 2024-07-11 Cila Therapeutic Inc. Anti-viral therapeutic agents and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013538A1 (en) * 1989-05-02 1990-11-15 Aktiebolaget Draco Organic salts of cysteine derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071102A1 (en) 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
AU2007338210B2 (en) 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
WO2010060875A1 (de) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Neue pulverförmige kristalline arzneimittel zur inhalation
EP3695835A1 (en) 2009-02-03 2020-08-19 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
SG195038A1 (en) 2011-05-19 2013-12-30 Savara Inc Dry powder vancomycin compositions and associated methods
JP5981123B2 (ja) 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
US9468612B2 (en) * 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
AU2013216703A1 (en) 2012-02-10 2014-09-25 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
ES2959419T3 (es) * 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013538A1 (en) * 1989-05-02 1990-11-15 Aktiebolaget Draco Organic salts of cysteine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. E. BUCHAN: "FORMULATION STUDIES ON CYSTEAMINE FOR THE TREATMENT OF NEPHROPATHIC CYSTINOSIS", 1 August 2011 (2011-08-01), pages 1 - 223, XP055404192, Retrieved from the Internet [retrieved on 20170906] *

Also Published As

Publication number Publication date
CA3026743C (en) 2024-05-28
US11369568B2 (en) 2022-06-28
DK3463325T3 (da) 2024-01-02
EP3463325A1 (en) 2019-04-10
WO2017212249A1 (en) 2017-12-14
KR102412212B1 (ko) 2022-06-23
GB201609940D0 (en) 2016-07-20
ZA201807852B (en) 2023-05-31
EP3463325B1 (en) 2023-11-08
JP7195934B2 (ja) 2022-12-26
ES2965017T3 (es) 2024-04-10
RU2018142841A (ru) 2020-06-04
FI3463325T3 (fi) 2023-12-19
SG11201810934TA (en) 2019-01-30
US20190175501A1 (en) 2019-06-13
CN109310654A (zh) 2019-02-05
BR112018075221A2 (pt) 2019-03-19
JP2019517541A (ja) 2019-06-24
NZ748596A (en) 2025-06-27
CA3096121C (en) 2022-11-15
RU2018142841A3 (enExample) 2020-09-30
CN122297397A (zh) 2026-06-30
AU2017277897A1 (en) 2018-12-20
MX2018014278A (es) 2019-03-14
CA3026743A1 (en) 2017-12-14
CA3096121A1 (en) 2017-12-14
BR112018075221B1 (pt) 2024-02-06
KR20190016957A (ko) 2019-02-19

Similar Documents

Publication Publication Date Title
CA3026743C (en) Microparticles comprising a sulphur-containing compound
US10905660B2 (en) Microparticles
ES2899621T3 (es) Polvos secos catiónicos que comprenden sal de magnesio
JP6392422B2 (ja) 吸入用の一価金属カチオン乾燥粉末
CA2981038C (en) Dry powder vancomycin compositions and associated methods
CA2468958C (en) Pulmonary delivery of aminoglycosides
US9539233B2 (en) Gallium formulation for the treatment and prevention of infectious diseases
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
RS52239B (sr) Farmaceutske formulacije i metode za tretman infekcija respiratornog trakta
CN102448439A (zh) 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
AU2012254999A1 (en) Dry powder vancomycin compositions and associated methods
CA2515262C (en) Treatment of bacterial diseases of the respiratory organs
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
ES2918193T3 (es) Polvo medicamentoso para administración por inhalación y un proceso del mismo
AU2022387278A1 (en) Methods for biofilm disruption
IL263540B2 (en) Microparticles that include a sulfur-containing compound
CN104208060A (zh) 一种青霉素类抗生素的吸入制剂
HK1089380B (en) Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)